IGF1 and Prader-Willi syndrome: This is in accordance with the current consensus guideline, which suggests that the GH dose in adults with PWS should be titrated to an IGF-I level between 0 and +2 SDS for age-matched controls for optimal effects and minimal risk of side effects [9].